About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists

EQ504 protects against gut damage in a mouse model of ulcerative colitis

EQ504 increases Treg stability and function while suppressing pathogenic Th17 responses

EQ504 promotes healing of intestinal epithelial cells by promoting anti-inflammatory cytokines

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that three posters were presented at IMMUNOLOGY2025, the annual meeting of The American Association of Immunologists taking place at the Hawaiʻi Convention Center in Honolulu, Hawaii, May 3 – 7.

“Decades of independent research have validated AhR as an important physiological regulator of immune homeostasis in barrier tissues such as the gut,” said Dr. Stephen Connelly, chief scientific officer at Equillium. “These data demonstrate the potent activity of EQ504 in suppressing inflammation and repair of intestinal tissues highlighting its potential as a powerful approach to treating ulcerative colitis, where poor mucosal healing limits the majority of patients achieving full clinical remission.”

Title: EQ504: A Novel AhR Agonist That Promotes Immune Tolerance Through Modulating T Cell Function

Abstract Number: 4678

Session Title: BA3P – Emerging Concepts in B Cell and T Cell Role in Autoimmune Disease II

Poster Number: P107

Lead Author: Jeanette Ampudia, Director, Immunology & Research Operations in Non-clinical Research, Equillium, Inc.

Presentation Type: Poster Session

Presentation Summary: EQ504 drives Treg stability and function while suppressing pathogenic Th17 responses, highlighting AhR modulation as a promising strategy to rebalance Teff/Treg ratios in immunoinflammatory diseases.

Title: EQ504: A Potent Derivative of the AhR Ligand ITE Demonstrates Efficacy in Modulating Inflammation and Promoting Healing in DSS-Colitis

Abstract Number: 9835

Session Title: IRM7P – Late-Breaking

Poster Number: P1076

Lead Author: Dalena Chu, Associate Scientist in Non-clinical Research, Equillium, Inc.

Presentation Type: Poster Session

Presentation Summary: EQ504 is a more potent inducer of CYP1A1 activity compared to its parent compound, ITE, is a stronger inducer of IL-10 and IL-22 gene expression compared to indirubin and effectively alleviates gut pathology in a mouse model of ulcerative colitis (UC), suggesting its potential as a potent therapeutic for UC patients via modulation of immune and gut epithelial cell function.

Title: Potent AhR Agonist EQ504 Facilitates Gut Epithelial Repair in Inflammatory Disease Models

Abstract Number: 4507

Session Title: MUC6P – Regulation of Mucosal Immunity

Poster Number: P1114

Lead Author: Valeria Marrocco, Senior Scientist in Non-clinical Research, Equillium, Inc.

Presentation Type: Poster Session

Presentation Summary: EQ504 is a strong inducer of the AhR pathway in intestinal epithelial cells, preserves the barrier function and promotes healing of intestinal epithelial cells by promoting IL22RA and IL10 expression.

The poster presentations are available on the Presentations page of Equillium’s website under the “EQ504” tab.

About EQ504

EQ504 is a potent and selective AhR modulator with a unique, multi-modal, non-immunosuppressive mechanism of action that is complementary to other inflammation and immunology agents. AhR is critical to barrier organ tissue physiology and immunology, maintaining barrier function and promoting tissue repair and regeneration, while regulating resident immune cells with anti-inflammatory responses. EQ504 has excellent drug-like properties making it amenable to be formulated for targeted, local delivery such as enteric coating for the treatment of ulcerative colitis or inhaled formulations for the treatment of inflammatory lung diseases.

About Equillium

Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company’s pipeline consists of several novel immunomodulatory assets and product platform targeting immuno-inflammatory pathways.

For more information, visit www.equilliumbio.com.

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “could”, “continue”, “expect”, “estimate”, “may”, “plan”, “outlook”, “future”, “potential” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements include, but are not limited to, statements regarding Equillium’s plans and strategies with respect to developing EQ504, including the initiation of clinical studies and the reporting of data therefrom; the expected timeline for initiating and reporting data from a Phase 1 study of EQ504; the ability to raise additional capital to fund development of EQ504; and the potential benefits of EQ504. Because such statements are subject to risks and uncertainties, many of which are outside of Equillium’s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: Equillium’s ability to execute its plans and strategies; Equillium’s ability to continue as a going concern; risks related to performing clinical and pre-clinical studies; whether the results from clinical and pre-clinical studies will validate and support the safety and efficacy of Equillium’s product candidates; changes in the competitive landscape; and Equillium’s ability to raise sufficient financing, which may not be available on acceptable terms or at all, to advance EQ504 and fund Equillium’s strategic plans. These and other risks and uncertainties are described more fully under the caption "Risk Factors" and elsewhere in Equillium's filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission’s website and on Equillium’s website under the heading “Investors.” Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Contacts

Corporate Contact

Michael Moore

Vice President, Investor Relations Officer & Head of Corporate Communications

619-302-4431

ir@equilliumbio.com

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.